A Phase 1b Study of Transforming Growth Factor-Beta Receptor I Inhibitor Galunisertib in Combination With Sorafenib in Japanese Patients With Unresectable Hepatocellular Carcinoma

Investigational New Drugs - Netherlands
doi 10.1007/s10637-018-0636-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-Beta Receptor I, in Combination With Standard Temozolomide-Based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Investigational New Drugs
OncologyPharmacology
2020English

High Serum Transforming Growth Factor- 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated With Sorafenib

Clinical Cancer Research
Cancer ResearchOncology
2015English

Sorafenib Continuation or Discontinuation in Patients With Unresectable Hepatocellular Carcinoma After a Complete Response

Oncotarget
Oncology
2015English

Phase I Trial of Sorafenib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Annals of Oncology
MedicineOncologyHematology
2017English

SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma

Investigational New Drugs
OncologyPharmacology
2011English

Clinical Phase I Study With an Insulin-Like Growth Factor-1 Receptor Inhibitor: Experiences in Patients With Squamous Non-Small Cell Lung Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Efficacy and Adverse Events of Transcatheter Arterial Chemoembolization in Combination With Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Retrospective Analysis of Transarterial Chemoembolization and Sorafenib in Chinese Patients With Unresectable and Recurrent Hepatocellular Carcinoma

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy